Manjusha Gaglani Selected Research

Manjusha Gaglani Research Topics

Disease

78	COVID-19 04/2024 - 01/2021
75	Human Influenza (Influenza) 04/2024 - 02/2014
36	Infections 03/2024 - 02/2014
3	Cough 01/2023 - 05/2016
3	Breakthrough Infections 01/2022 - 01/2021
2	Respiratory Insufficiency (Respiratory Failure) 12/2023 - 03/2022
2	Critical Illness (Critically Ill) 05/2023 - 01/2023
2	Fever (Fevers) 10/2022 - 01/2018
2	Disease Progression 10/2022 - 11/2021
2	Pneumonia (Pneumonitis) 01/2022 - 01/2018
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020 - 01/2018
1	Mental Disorders (Mental Disorder) 03/2024
1	Hypoxia (Hypoxemia) 12/2023
1	Renal Insufficiency (Renal Failure) 12/2023
1	Vision Disorders (Hemeralopia) 11/2023
1	Chills 10/2022
1	Hepatitis D 10/2022
1	Coinfection 10/2022
1	Thrombocytopenia (Thrombopenia) 04/2022
1	Thrombosis (Thrombus) 04/2022
1	Asymptomatic Infections 08/2021
1	Drug-Related Side Effects and Adverse Reactions 12/2020
1	Frailty 01/2019
1	Pharyngitis (Sore Throat) 01/2018
1	Sinusitis 01/2018
1	Bronchitis 01/2018
1	Herpesviridae Infections (Herpesvirus Infection) 02/2014
1	Measles 10/2011
1	Mumps 10/2011
1	Chickenpox 10/2011
1	Rubella (German Measles) 10/2011

Drug/Important Bio-Agent (IBA)

103	VaccinesIBA 03/2024 - 10/2011
46	Influenza Vaccines (Influenza Vaccine)FDA Link 02/2024 - 02/2014
38	mRNA VaccinesIBA 02/2024 - 01/2021
36	Messenger RNA (mRNA)IBA 03/2024 - 01/2021
36	COVID-19 VaccinesIBA 03/2024 - 04/2021
11	BNT162 VaccineIBA 01/2023 - 01/2021
10	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2023 - 02/2014
7	N-(2-cyanoethylene)urea (BA 1)IBA 09/2023 - 07/2022
6	Antiviral Agents (Antivirals)IBA 03/2022 - 02/2014
5	Combined VaccinesIBA 01/2024 - 01/2021
5	AntibodiesIBA 12/2023 - 01/2015
5	2019-nCoV Vaccine mRNA-1273IBA 03/2022 - 01/2021
5	Hemagglutinins (Hemagglutinin)IBA 01/2021 - 01/2015
4	Neutralizing AntibodiesIBA 09/2023 - 01/2022
4	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023 - 07/2022
3	Proteins (Proteins, Gene)FDA Link 11/2023 - 10/2022
3	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 09/2014
2	Oxygen (Dioxygen)IBA 12/2023 - 10/2023
2	Immunoglobulin G (IgG)IBA 11/2023 - 09/2021
2	Viral RNAIBA 11/2023 - 01/2021
2	AntigensIBA 09/2023 - 01/2023
2	Ad26COVS1IBA 10/2022 - 10/2021
2	Attenuated VaccinesIBA 01/2021 - 10/2017
2	Inactivated VaccinesIBA 01/2021 - 12/2018
2	Neuraminidase (Sialidase)IBA 09/2016 - 01/2015
1	Respiratory Syncytial Virus VaccinesIBA 04/2024
1	perfluorooctane sulfonic acidIBA 12/2023
1	perfluorooctanoic acidIBA 12/2023
1	perfluoro-n-nonanoic acidIBA 12/2023
1	perfluorohexanesulfonic acidIBA 12/2023
1	Nucleocapsid ProteinsIBA 11/2023
1	RNA (Ribonucleic Acid)IBA 11/2023
1	EpitopesIBA 09/2023
1	NucleoproteinsIBA 10/2022
1	COVID-19 vaccine booster shotIBA 04/2022
1	Stored Messenger RNAIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 12/2021
1	Nucleic AcidsIBA 11/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019
1	CI 22IBA 01/2019
1	Hepatitis A Vaccines (Hepatitis A Vaccine)IBA 10/2011

Therapy/Procedure

21	Ambulatory Care (Outpatient Care) 03/2024 - 09/2014
7	Artificial Respiration (Mechanical Ventilation) 04/2024 - 11/2021
2	Therapeutics 10/2023 - 09/2014
1	Noninvasive Ventilation 10/2023
1	Cannula 10/2023
1	Critical Care (Surgical Intensive Care) 01/2022
1	Mechanical Ventilators (Ventilator) 12/2021
1	Length of Stay 12/2021